Bolt Biotherapeutics to Participate in Upcoming March Conferences
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company focused on cancer immunotherapies, has announced its participation in two major healthcare conferences this March. The company will deliver a presentation at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 p.m. EST. Additionally, Bolt's management team will engage in one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 10, 2025.
Bolt Biotherapeutics (Nasdaq: BOLT), un'azienda biofarmaceutica in fase clinica focalizzata sulle immunoterapie per il cancro, ha annunciato la sua partecipazione a due importanti conferenze sanitarie questo marzo. L'azienda presenterà un intervento al TD Cowen 45° Annual Health Care Conference il 4 marzo 2025, alle 15:10 EST. Inoltre, il team di gestione di Bolt parteciperà a incontri individuali presso il Leerink Partners Global Healthcare Conference il 10 marzo 2025.
Bolt Biotherapeutics (Nasdaq: BOLT), una empresa biofarmacéutica en etapa clínica centrada en las inmunoterapias contra el cáncer, ha anunciado su participación en dos importantes conferencias de salud este marzo. La empresa realizará una presentación en la TD Cowen 45ª Conferencia Anual de Atención Médica el 4 de marzo de 2025, a las 3:10 p.m. EST. Además, el equipo directivo de Bolt participará en reuniones uno a uno en la Leerink Partners Global Healthcare Conference el 10 de marzo de 2025.
Bolt Biotherapeutics (Nasdaq: BOLT), 암 면역 치료에 중점을 둔 임상 단계의 생명공학 회사가 이번 3월 두 개의 주요 의료 회의에 참여한다고 발표했습니다. 이 회사는 2025년 3월 4일 오후 3시 10분 EST에 TD Cowen 제45회 연례 의료 회의에서 발표를 진행할 예정입니다. 또한, Bolt의 경영진은 2025년 3월 10일 Leerink Partners 글로벌 의료 회의에서 일대일 회의에 참여할 것입니다.
Bolt Biotherapeutics (Nasdaq: BOLT), une entreprise biopharmaceutique en phase clinique axée sur les immunothérapies contre le cancer, a annoncé sa participation à deux grandes conférences de santé ce mois de mars. L'entreprise fera une présentation lors de la 45e Conférence Annuelle de Soins de Santé TD Cowen le 4 mars 2025 à 15h10 EST. De plus, l'équipe de direction de Bolt participera à des réunions individuelles lors de la Conférence Mondiale de Soins de Santé de Leerink Partners le 10 mars 2025.
Bolt Biotherapeutics (Nasdaq: BOLT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Immuntherapien gegen Krebs konzentriert, hat seine Teilnahme an zwei wichtigen Gesundheitskonferenzen im März bekannt gegeben. Das Unternehmen wird am 4. März 2025 um 15:10 Uhr EST eine Präsentation auf der TD Cowen 45. jährlichen Gesundheitskonferenz halten. Darüber hinaus wird das Management-Team von Bolt am 10. März 2025 an Einzelgesprächen auf der Leerink Partners Global Healthcare Conference teilnehmen.
- None.
- None.
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March:
- TD Cowen 45th Annual Health Care Conference
Company presentation on Tuesday, March 4, 2025 at 3:10 p.m. EST (1:10 p.m. PST)
- Leerink Partners Global Healthcare Conference
Participating in 1x1 meetings on Monday, March 10, 2025
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting Dectin-2, and BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of seven different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt Biotherapeutics is also developing multiple Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.
Investor Relations and Media Contact:
Matthew DeYoung
Argot Partners
(212) 600-1902
boltbio@argotpartners.com
FAQ
When is Bolt Biotherapeutics (BOLT) presenting at the TD Cowen Healthcare Conference in 2025?
Which healthcare conferences is BOLT attending in March 2025?
What type of meetings will BOLT conduct at the Leerink Partners Conference?
What is the main focus of Bolt Biotherapeutics' research and development?
